Currently, the only clinical experience of CDK4/6 inhibitors in RCC is a phase I trial evaluating the combination of Abemaciclib and Sunitinib in metastatic RCC (NCT03905889). This evidence concerns the gene CDK4 and renal cell carcinoma.